Skip to main content

Preclinical Development Activities of FLAG-003

Printer-friendly versionPrinter-friendly versionSend by emailSend by email
Award date: 
Mar 6, 2015
Award amount: 
$250,000
Organization name: 
FLAG Therapeutics Inc
Principal Investigator: 
Sorgi, Frank L
Grant program category: 
Business Financing
Grant program name: 
Small Business Research Loan
Region: 
Research Triangle

FLAG-003 is being developed as a treatment for Glioblastoma Multiforme (GBM), the most aggressive form of brain cancer. Prior to initiating clinical trials, FLAG needs to have the FLAG-003 compound manufactured in an appropriate and registered facility and key animal studies need to be performed in a registered facility.

Fiscal year: 
2015